Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 8:38 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 961–984 of 2,512 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: RAPID Clear all

Conditions: Pneumonia, Bacterial
Interventions: 13C-urea breath test; Device
Lead sponsor: University of New Mexico; Other
Eligibility: 18 Years to 85 Years
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: Parkinson Disease, Gaucher Disease, Idiopathic Rapid Eye Movement Sleep Disorder
Interventions: Not listed
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years to 85 Years
Enrollment: 56 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2018
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Keloid Scar
Interventions: Soliton's Acoustic Scar Reduction (SAR); Device
Lead sponsor: Soliton; Industry
Eligibility: 18 Years and older
Enrollment: 9 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Scottsdale, Arizona

Conditions: Cardiovascular Diseases
Interventions: Web-based Heart Healthy Program; Behavioral
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: 21 Years to 70 Years
Enrollment: 300 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Alexandria, Virginia

Conditions: Covid19
Interventions: INDICAID™ COVID-19 Rapid Antigen Test; Diagnostic Test
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 5 Years and older
Enrollment: 297 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Oakland, California

Conditions: PULSE OXIMETRY
Interventions: NO INTERVENTION; Device
Lead sponsor: Philips Clinical & Medical Affairs Global; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 86 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Louisville, Colorado

Conditions: Dysmenorrhea, Headache, Migraine, Fatigue, Nausea, Mood Disturbance
Interventions: Pure Femme Tablets; Drug
Lead sponsor: Pure Green; Industry
Eligibility: 21 Years and older · Female only
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Sterling Heights, Michigan

Conditions: Obesity, Overweight, Weight Loss
Interventions: Physician Counseling, Health Educator, Phone Counseling, Health promotion materials on physical activity and nutrition; Behavioral
Lead sponsor: University of California, San Diego; Other
Eligibility: 11 Years to 13 Years
Enrollment: 106 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: La Jolla, California

Conditions: Kidney Stone, Stone, Kidney
Interventions: Not listed
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years to 70 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Acute Bleeding on Long-Term Anticoagulation Therapy, Hemorrhage, Significant Bleeding in Patients With a Coagulopathy (Prolonged Thrombin Time), Urgent Reversal of Vitamin K Antagonist (VKA) Anticoagulation
Interventions: 4-factor prothrombin complex concentrate (4FPCC); Drug
Lead sponsor: HealthPartners Institute; Other
Eligibility: 18 Years to 125 Years
Enrollment: 79 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Saint Paul, Minnesota

Conditions: Malignant Melanoma, Neoplasms
Interventions: Rifampin, Vemurafenib; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 4
States / cities: Rogers, Arkansas • Pleasant Hill, California • Middletown, Ohio + 1 more

Conditions: Opioid-Related Disorders, Pain, Acute, Pain, Postoperative
Interventions: Norco 5Mg-325Mg Tablet, GRT7014 - Abuse Deterrent Tablet; Drug
Lead sponsor: Grünenthal GmbH; Industry
Eligibility: 18 Years to 55 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 1
States / cities: Lenexa, Kansas

Conditions: Substance Use Disorders, HIV
Interventions: Population level patient portal based substance involvement screening, Usual Care Substance Use Involvement Screening; Behavioral
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years and older
Enrollment: 900 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Hiv, HIV Infections
Interventions: 60-Minutes-For-Health, Time-and-Attention Control Session; Behavioral · Other
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years to 85 Years
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 2
States / cities: San Diego, California

Conditions: Healthy Volunteers
Interventions: Fedratinib, Digoxin, Rosuvastatin, Metformin; Drug
Lead sponsor: Celgene; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Influenza
Interventions: Oseltamivir, Peramivir; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 100 Years
Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 2
States / cities: Phoenix, Arizona • Baltimore, Maryland

Conditions: Hospital Acquired Condition
Interventions: The Beat Analytics System (BAS); Device
Lead sponsor: Bob Topp; Other
Eligibility: 18 Years and older
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Toledo, Ohio

Conditions: Cannabis Use Disorder, Stimulant Use Disorder, Opioid Use Disorder, Tobacco Use Disorder, Alcohol Use Disorder, Sedative, Hypnotic, or Anxiolytic Use Disorders
Interventions: Emotional Brain Training, Standard addiction counseling and medical therapy; Behavioral · Other
Lead sponsor: Loma Linda University; Other
Eligibility: 18 Years and older
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: San Bernardino, California

Conditions: Gastric Antral Vascular Ectasia, Cirrhosis, Chronic Kidney Disease
Interventions: Gastric Emptying Breath Test; Diagnostic Test
Lead sponsor: Mayo Clinic; Other
Eligibility: 19 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Cognitive Impairment
Interventions: Speed of Processing Training, Transfer Package from CI Therapy; Behavioral
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Smoking Cessation
Interventions: Contingency management, Nicotine replacement therapy, Varenicline, Additional behavioral support; Behavioral · Drug
Lead sponsor: Yale University; Other
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Renal Transplantation, Graft Rejection
Interventions: Thymoglobulin [Anti-Thymocyte Globulin (Rabbit)]; Drug
Lead sponsor: Genzyme, a Sanofi Company; Industry
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2005
U.S. locations: 19
States / cities: Little Rock, Arkansas • Los Angeles, California • San Diego, California + 13 more

Conditions: Non-Alcoholic Fatty Liver Disease, Non Alcoholic Fatty Liver, Non Alcoholic Steatohepatitis, NAFLD, NASH
Interventions: Hyperpolarized (HP) 13C, Hyperpolarized 13C-Urea, Magnetic Resonance Imaging, Saline Flush; Drug · Procedure
Lead sponsor: Michael Ohliger, MD PhD; Other
Eligibility: 18 Years and older
Enrollment: 44 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2025
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Healthy Participants
Interventions: AZD8965, Placebo; Drug · Other
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 147 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Glendale, California

Search by objective public record fields.

Urease Breath Test for Rapid Characterization of Pneumonia

Detecting Dopaminergic Deficits in Individuals At-risk for Parkinsonism

Proof of Concept (POC) Study of the Soliton's Acoustic Scar Reduction (ASR) Treatment for the Treatment of Keloid Scar

A Web-Based Cardiovascular Intervention for the Workplace

Evaluation of the INDICAID™ COVID-19 Rapid Antigen Test

SPO2 VALIDATION STUDY - PHILIPS FAST 2025

Sublingual Tablets With Cannabinoid Combinations for the Treatment of Dysmenorrhea

PACE-PC: Primary Care Management of Adolescent Obesity

Kidney Stone Inflammation

Fixed Versus Variable Dosing of 4-factor Prothrombin Complex Concentrate for Emergent Warfarin Reversal

A Pharmacokinetics (PK) Study to Investigate the Effect of Rifampin on PK of Vemurafenib (Zelboraf)

A Comparison of Plasma Concentrations of Hydrocodone and Acetaminophen After Administration of a New and a Marketed Tablet Formulation Under Fasted and Fed Conditions in Healthy Adults

Achieving Equity in Patient Outcome Reporting for Timely Assessments of Life With HIV and Substance Use

Instacare - Rapid ART Initiation Among Persons With HIV and Out of Care

Influence of Fedratinib on the Pharmacokinetics of the Transporter Probe Substrates Digoxin, Rosuvastatin, and Metformin

ED Influenza Therapeutic Pilot Study: Oseltamivir vs. Peramivir

The Effect of Real Time Analytics on Adverse Events Among Hospitalized Patients

Emotional Brain Training for Addiction Medicine Treatment - A Pilot Study

Prevalence of Gastric Motor Dysfunction and Upper GI Symptoms in Gastric Antral Vascular Ectasias

Improving Thinking in Everyday Life: Pilot Study A

A Smoking Cessation Intervention for Yale Dining Employees

A Study to Evaluate the Effect of Thymoglobulin and Reduced Doses of Steroids to Prevent Renal Transplant Rejection

Hyperpolarized Pyruvate (13C) Magnetic Resonance Imaging In Patients With Fatty Liver Disease

A Single and Multiple Ascending Dose Study to Investigate the Safety, Tolerability, and Pharmacokinetics of AZD8965 in Healthy Participants (Including Japanese and Chinese Participants) and an Open-label Cohort to Assess the Effect of Food on the Pharmacokinetics of AZD8965 in Healthy Participants